AstraZeneca $27B wipeout as Wainua late trial misses cardiovascular target
A failed late-stage heart study triggered a swift market punishment, forcing investors and boards to reset timelines and risk.
By Hessa Al-Faleh·· 3 min
Loading the Newsroom
Curating from trusted global sources…